{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-063497","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2026-09-25T11:04:25+00:00","discovered_at":"2026-09-25T11:05:00.540411+00:00","generated_at":"2026-10-12T13:17:55.031124+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"C4 Therapeutics cemsidomide biomarker data positive; 75 µg elranatamab combo declared safe, Phase 1b advances","bullets":["Phase 1 cemsidomide + dexamethasone in 62 heavily pre-treated RRMM patients showed coordinated CD8+ T-cell activation and NK-cell reprogramming at the 75 µg and 100 µg doses.","Phase 1b cemsidomide + elranatamab (ELREXFIO): first two patients showed CD8+ effector memory T-cell expansion (elevated HLA-DR) with no rise in exhaustion markers PD-1, TIM-3, LAG3.","Safety data review committee declared the 75 µg cemsidomide dose with elranatamab safe after the first six-patient cohort; trial advancing to a 100 µg escalation cohort and a 75 µg expansion cohort.","Data from all Phase 1b cohorts evaluated are expected in mid-2027; results presented at the 23rd International Myeloma Society Annual Meeting on September 25, 2026.","CMO Len Reyno said the data reinforce a strategy to establish cemsidomide as a backbone therapy in multiple myeloma for immune-based combinations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-063497","json":"https://secwatch.observer/filing/0001628280-26-063497.json","markdown":"https://secwatch.observer/filing/0001628280-26-063497.md","text":"https://secwatch.observer/filing/0001628280-26-063497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026063497/0001628280-26-063497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026063497/cccc-20260925.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:17:55.031124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}